Overview

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Status:
RECRUITING

Trial end date:
2032-10-01

Target enrollment:

Participant gender:

Summary

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Phase:

PHASE3

Details

Lead Sponsor:

Stemline Therapeutics, Inc.

Treatments:

Anastrozole
elacestrant
exemestane
Letrozole
Tamoxifen